leadf
logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical advancing its coronavirus (COVID-19) Cannabinoid Sol-Gel Program

With the successful completion of its COVID-19 CBD Program, a sol-gel based formulation has been developed to deliver medicinal cannabis

PreveCeutical Medical Inc. - PreveCeutical Medical Inc says it is advancing its coronavirus (COVID-19) Cannabinoid Sol-Gel Program
The program seeks to prevent SARS-CoV-2 (the virus that causes COVID-19) infection in nasal tissue

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FRA:18H) on Tuesday said it is advancing its coronavirus (COVID-19) Cannabinoid Sol-Gel Program. 

With the successful completion of the COVID-19 CBD Program, a sol-gel based formulation has been developed to deliver medicinal cannabis, the company said in a statement. 

Vancouver-based PreveCeutical added that it will provide further information once the final report for this program is received. 

READ: PreveCeutical Medical set to submit a revised application for potential coronavirus therapy funding

With the use of a nose applicator, the sustained-released Sol-Gel formulations allows for the direct and prolonged delivery of cannabinoids to a patient's central nervous system. The program is designed to prevent SARS-CoV-2 (the virus that causes COVID-19) infection in nasal tissue.

"We are very pleased to repurpose the outcomes of our past cannabinoid sol-gel program to develop a specific formulation with the potential to address COVID-19,” said Stephen Van Deventer. “We are looking forward to receiving the final report, at which time we will look to file a patent on the formulation science and move towards the start of the clinical trials process."

The company noted that is not making any express or implied claims that its product candidate has the ability to eliminate, cure, or contain COVID-19 at this time.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: PreveCeutical Medical Inc.

Price: 0.035 CAD

CSE:PREV
Market: CSE
Market Cap: $17.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 23/7/20

2 min read